Senores Pharmaceuticals IPO Date, Review, Price, Allotment Details

Senores Pharmaceuticals IPO Details

Senores Pharmaceuticals IPO Market Lot

The Senores Pharmaceuticals IPO minimum market lot is 38 shares with ₹14,858 application amount. The retail investors can apply up-to 13 lots with 494 shares or ₹1,93,154 amount.

Senores Pharmaceuticals IPO Dates

The Senores Pharmaceuticals IPO date is December 20 and the close date is December 24. The Senores Pharmaceuticals IPO allotment will be finalized on December 26 and the IPO listing on December 30.

Promoters of Senores Pharmaceuticals IPO

The promoters of the company are Swapnil Jatinbhai Shah and Ashokkumar Vijaysinh Barot

About Senores Pharmaceuticals IPO

Senores is one of the great pharmaceuticals focusing on generic medicine. It has also been certified by global food and drug authorities. Nowadays it is committed to providing good quality and manufacturing products to raise new demand in the global healthcare industry. At present, they have a goal of innovation, production, and manufacturing verticals and also have the vision to make more affordable and accessible healthcare, especially for varied types of products. Moreover, they are providing a dynamic strategy, offering them access to products that are good to go. Noticeably, they have the strength of identifying, producing, specialty, underpenetrated, and complex pharmaceutical products, and received the reliability of customers to choose them over and over. It is focused on the US and Canadian markets, simultaneously 43 countries have also felt the presence of them. The company also manufactures critical care injectables and active pharmaceutical ingredients (APIs).

Senores Pharmaceuticals IPO Company Financial Report

The company reported revenue of ₹217.34 crores in 2024 against ₹39.02 crore in 2023. The company reported loss of ₹32.71 crores in 2024 against Profit of ₹8.43 crores in 2023.

Amount ₹ in Crores

Senores Pharmaceuticals IPO Valuation – FY2024

Check Senores Pharmaceuticals IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.

Peer Group Comparison

Objects of the Issue

• Funding the capital expenditure requirements by investment in of one of our Subsidiaries, Havix Group, Inc. d/b/a Aavis Pharmaceuticals (“Havix”), for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility;
• Re-payment/pre-payment, in full or in part, of certain borrowings availed by our Company and our Subsidiaries, namely, Havix, Ratnatris Pharmaceutical Private Limited (“Ratnatris”) and Senores Pharmaceuticals Inc. (“SPI”);
• Funding the working capital requirements of our Company and our Subsidiaries, namely, SPI and Ratnatris; and
• Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes.

Senores Pharmaceuticals IPO Review

• Canara Bank –
• DRChoksey FinServ –
• Emkay Global –
• Hem Securities –
• IDBI Capital –
• Marwadi Shares –
• Nirmal Bang –
• SBICAP Securities –
• Sharekhan –
• SMC Global –
• Sushil Finance –
• Swastika Investmart –
• Ventura Securities –
• Geojit –
• Reliance Securities –
• Capital Market –
• BP Wealth –
• ICICIdirect –
• Choice Broking –

Senores Pharmaceuticals IPO Registrar

Link Intime India Private Limited
Phone: +91 8108114949
E-mail: [email protected]
Website: https://linkintime.co.in/initial_offer/

IPO Lead Managers aka Merchant Bankers

• Equirus Capital Private Limited
• Ambit Private Limited
• Nuvama Wealth Management Limited

Company Address

Senores Pharmaceuticals Limited
1101 to 1103,
11th floor, South Tower, ONE 42
Opposite Jayantilal Park,
Ambali Bopal Road, Ahmedabad,
Ahmedabad, Gujarat,
India, 380054
Phone: +91 -79-29999857
Email: [email protected];
Website: www. senorespharma.com

Senores Pharmaceuticals IPO FAQs